



Spasenija Savic

Kontakt

Spasenija Savic

Publikationen (12)

Savic S, Soltermann A, Zweifel R, Zetl A, von Gunten M, Singer G, Rössle M, Jasarevic Z, Letovanec I, McKee T, Komminoth P, Jochum W, Fleischmann A, Diebold J, Cathomas G, Eppenberger-Castori S, Berezowska S, Bubendorf L. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. *Virchows Arch* 2019; 475:67-76.

Trefny M, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K, Zippelius A, Geier F, Thommen D, Rothschild S, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M, Berner F, Kashyap A, Kaiser M, Herzig P, Pochtrager S, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. *Clin Cancer Res* 2019; 25:3026-3034.

Metaxas Y, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, O'Byrne K, Petrausch U, Wolleb S, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. *J Thorac Oncol* 2018

Savic S, Kerr K, Bisig B, Tornillo L, Grieshaber S, Baschiera B, Jochum W, Zimmermann A, Diebold J, Bubendorf L. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. *Lung Cancer* 2015; 89:104-9.

Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. *Clin Lung Cancer* 2015; 16:358-65.

Holbro A, Lehmann T, Girsberger S, Stern M, Gambazzi F, Lardinois D, Heim D, Passweg J, Tichelli A, Bubendorf L, Savic S, Hostettler K, Grendelmeier P, Halter J, Tamm M. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2013; 19:973-80.

Tapia C, Glatz K, Obermann E, Grilli B, Barascud A, Herzog M, Schönegg R, Savic S, Bubendorf L. Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology. *Cancer Cytopathol* 2011; 119:404-10.

Savic S, Herman J, Clark D, Zlobec I, Schönegg R, Spieler P, Loosli H, Bode B, Herzog M, Barascud A, Grilli B, Franco N, Bubendorf L. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. *Chest* 2010; 138:137-44.

Baty F, Tamm M, Kehren J, Buess M, Budach W, Marrer E, Savic S, Bubendorf L, Pless M, Schumacher M, Kaiser S, Facompre M, Brutsche M. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. *American journal of respiratory and critical care medicine* 2010; 181:181-8.

Zlobec I, Raineri I, Schneider S, Schönegg R, Grilli B, Herzog M, Savic S, Bubendorf L. Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. *Lung cancer (Amsterdam, Netherlands)* 2009

Savic S, Casella R, Zellweger T, Forster T, Sulser T, Gasser T, Schönegg R, Spieler P, Dalquen P, Eichenberger T, Mattarelli G, Lehmann K, Schmauss M, Engeler D, Thalmann G, Zlobec I, Bubendorf L. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. *International journal of cancer. Journal international du cancer* 2009; 124:2899-904.

Tapia C, Feichter G, Terracciano L, Cathomas G, Zlobec I, Barascud A, Herzog M, Grilli B, Novotny H, Schönegg R, Wagner U, Savic S, Bubendorf L. HER2 gene status in primary breast cancers and matched distant metastases. Breast cancer research : BCR 2007; 9:R31.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch